[The use of monoclonal antibodies in the detection of small cell lung cancer metastases in bone marrow].
Expression of a number of antigens associated with small cell lung cancer (SCLC) have been proposed as a marker of malignancy and the diagnostic tool for the staging procedures and important prognostic factor. Since the bone marrow (BM) was described as a frequent site for SCLC metastases, we have decided to assess clinical importance of cancer cells detection in BM, using immunofluorescence with MAC-1, MAC-31, NSE and anti-Fucosyl-GM1 (PF3) antibodies. The group of 32 patients with SCLC was assessed using our panel of antibodies. Control group consisted of 5 patients with other malignancies (3 patients with malignant lymphoma, 1 with chronic lymphocytic leukaemia and 1 with non-SCLC). The study revealed no correlation between the expression of SCLC markers in patients BM and the cancer treatment outcome measured as a response for treatment, time to progression, and survival time, and no significant difference was found between the patients and control group.
Obłakowski
P
P
III Kliniki Gruźlicy i Chorób Płuc, Instytutu Gruźlicy i Chorób Płuc w Warszawie.
Pacuszka
T
T
Rogińska
E
E
Remiszewski
P
P
Załeska
J
J
Zych
J
J
Roszkowski
K
K
Rowińska-Zakrzewska
E
E
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000032:analysis*; D019046:Bone Marrow Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000556:secondary*; D018288:Carcinoma, Small Cell / Q000175:diagnosis* / Q000401:mortality / Q000556:secondary*; D018450:Disease Progression; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor